CD8A and neoplasm: Interestingly, subclonal MHC-I mutations and MHC-I LOH were both associated with high CD8 (cytolytic) activity in the affected lesions [52,53], indicative of the ongoing tumor immune editing that drives subclonal evolution, particularly in the context of immunotherapy.